Study to compare effect of oral drug in vitiligo (Tofacitinib) along with ultraviolet ray therapy versus only ultraviolet ray therapy in vitiligo patients
Phase 4
- Conditions
- Health Condition 1: L80- Vitiligo
- Registration Number
- CTRI/2022/02/040658
- Lead Sponsor
- Indian Association of Dermatologists Venereologists Leprologists IADV
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. All clinically diagnosed cases of unstable vitiligo
2. No use of any systemic therapy for 4 weeks prior to enrollment in the study
3. Informed consent obtained
4. Willing for twice weekly treatment with narrow band ultraviolet B phototherapy.
Exclusion Criteria
1. Pregnant and lactating women.
2. Known Hyperlipidemic individual
3. Patient taking known photosensitizer drugs or immunosuppressive therapy.
4. Concomitant immune defects, heart disease, renal failure, malignancy.
5. Neurological or psychiatric disorders.
6. History of photosensitivity or photomediated disorder.
7. Participation in any clinical trial within the last 3 months
8. Substance or alcohol abuse.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method